English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, September 25, 2023
致力于开发中国双抗疗法的生物技术公司武汉友芝友生物于香港联交所主板正式挂牌
致力於開發中國雙抗療法的生物技術公司武漢友芝友生物於香港聯交所主板正式掛牌
A biotechnology company dedicated to developing BsAb-based therapies in China, YZY Biopharma Officially Listed on Main Board of SEHK
Wednesday, September 13, 2023
专注于中国双抗的开发 武汉友芝友生物宣布于港交所主板上市计划
專注於中國雙抗的開發 武漢友芝友生物宣佈於港交所主板上市計劃
Focusing on the development of BsAbs in China, YZY Biopharma Announces Proposed Listing on the Main Board of SEHK

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575